Using 3D scanning to measure swelling in head and neck lymphedema
Head and Neck Cancer Patient Symptom and Oncologic Outcomes as a Function of Head and Neck Volume Changes
This study is testing a new 3D scanning tool to see if it can help track swelling in the head and neck for patients with lymphedema over a year.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ohio State University Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Columbus, Ohio) |
| Trial ID | NCT05243069 on ClinicalTrials.gov |
What this trial studies
This trial explores a novel mobile 3D scanning application designed to accurately measure and monitor lymphedema in the head and neck region. Patients will undergo 3D scans before surgery and every three months for up to a year to track changes in swelling. The study aims to correlate these volumetric measurements with patient well-being and disease progression, enhancing the understanding and management of head and neck lymphedema.
Who should consider this trial
Good fit: Ideal candidates include patients with conditions that lead to head and neck lymphedema who can provide informed consent.
Not a fit: Patients with health conditions that affect compliance or those with significant facial hair may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved monitoring and management of lymphedema, enhancing patient outcomes.
How similar studies have performed: While the use of 3D scanning in other medical fields has shown promise, this specific application for head and neck lymphedema is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with pathologies leading to head and neck lymphedema * Individuals with minimal or no facial hair * Patients of sound mentation, who are able to execute informed decision-making Exclusion Criteria: * Any health conditions or history of non-compliance that affect the study will preclude study participation
Where this trial is running
Columbus, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Roman Skoracki, MD — Ohio State University Comprehensive Cancer Center
- Study coordinator: The Ohio State Comprehensive Cancer Center
- Email: OSUCCCClinicaltrials@osumc.edu
- Phone: 800-293-5066
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.